Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 04, 2022

SELL
$30.71 - $45.71 $5,619 - $8,364
-183 Closed
0 $0
Q3 2019

Nov 05, 2019

BUY
$140.29 - $189.96 $7,014 - $9,498
50 Added 37.59%
183 $26,000
Q1 2019

May 15, 2019

SELL
$89.33 - $163.65 $14,918 - $27,329
-167 Reduced 55.67%
133 $21,000
Q4 2018

Jan 31, 2019

BUY
$81.94 - $139.71 $24,582 - $41,913
300 New
300 $29,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Benjamin F. Edwards & Company, Inc. Portfolio

Follow Benjamin F. Edwards & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.